Cancer

Main Content

Niraparib/Bevacizumab Study

Study title

Phase 2, single-arm, open label study to evaluate the safety and efficacy of Niraparib combined with Bevacizumab as maintenance treatment in patients with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer following front-line platinum-based chemotherapy with bevacizumab

  • Principal Investigator: Dr. Kelly Wilkinson

Purpose

This study is for looking at the safety and efficacy of experimental drugs in patients with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.

Who can participate

Those eligible to participate in this study include:

  • Women 18 years and older with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer

For more information

  • Sandra Powe
    University of Mississippi Medical Center 
    2500 N. State St. 
    Jackson MS 39216 
    (601) 984-1965
  • IRB Number: 2018-0046